6635-88-7

Basic information

• Product Name: (1-OXY-PYRIDIN-3-YL)-ACETONITRILE
• Synonyms: 3-(CYANOMETHYL)-1-PYRIDINIUMOLATE;(1-OXY-PYRIDIN-3-YL)-ACETONITRILE;3-(Cyanomethyl)pyridin-1-ium-1-olate;2-(1-oxidopyridin-1-ium-3-yl)acetonitrile
• CAS NO: 6635-88-7
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.14
• Product Categories: Heterocyclic Building Blocks
• Mol File: 6635-88-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 398.9°C at 760 mmHg
• Flash Point: 195.1°C
• Appearance: /
• Density: 1.1g/cm³
• Vapor Pressure: 1.42E-06mmHg at 25°C
• Refractive Index: 1.555
• CAS DataBase Reference: (1-OXY-PYRIDIN-3-YL)-ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (1-OXY-PYRIDIN-3-YL)-ACETONITRILE(6635-88-7)
• EPA Substance Registry System: (1-OXY-PYRIDIN-3-YL)-ACETONITRILE(6635-88-7)

Safety Data

• Hazardous Substances Data: 6635-88-7(Hazardous Substances Data)

Usage

General Description

(1-OXY-PYRIDIN-3-YL)-ACETONITRILE is a chemical compound with the chemical formula C7H6N2O. It is a derivative of pyridine, containing a nitrile group and an oxygen atom attached to the third carbon of the pyridine ring. (1-OXY-PYRIDIN-3-YL)-ACETONITRILE is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules. It may also be utilized as a precursor in the production of agrochemicals, pharmaceuticals, and other fine chemicals. Its chemical structure and properties make it an important intermediate in the production of various chemical products.

InChI:InChI=1/C7H6N2O/c8-4-3-7-2-1-5-9(10)6-7/h1-2,5-6H,3H2

Upstream product

• 6959-48-4 3-chloromethylpyridinium chloride 
• 6443-85-2 3-pyridinylacetonitrile 

Downstream Products

• 99310-62-0 (5-hydroxy-[3]pyridyl)-acetonitrile 
• 39891-09-3 (6-chloro-pyridin-3-yl)-acetonitrile 
• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 5912-34-5 2-cyano-pyridin-3-yl-acetonitrile 
• 1393900-78-1 2-(2-(2-(2-((4-(1-ethylpiperidin-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)pyridin-3-yl)acetamide 
• 1393900-77-0 2-(2-(2-(2-((4-(piperidin-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)pyridin-3-yl)acetamide 
• 1393901-86-4 tert-butyl 3-(4-((4-(2-(3-(2-amino-2-oxoethyl)pyridin-2-yl)ethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperidine-1-carboxylate 
• 1393901-85-3 2-(2-(2-(2-((4-(1-(tert-butoxycarbonyl)piperidin-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)pyridin-3-yl)acetic acid 
• 1393901-84-2 tert-butyl 3-(4-((4-(2-(3-(2-methoxy-2-oxoethyl)pyridin-2-yl)ethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperidine-1-carboxylate 
• 1393901-83-1 tert-butyl 3-(4-((4-((3-(2-methoxy-2-oxoethyl)pyridin-2-yl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperidine-1-carboxylate 
• 1393900-76-9 2-(2-(2-(2-((4-(1-ethylpiperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)pyridin-3-yl)acetamide 
• 1393900-71-4 2-(2-(2-(2-((4-(1-methylpiperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)pyridin-3-yl)acetamide 
• 1393900-70-3 2-(2-(2-(2-((4-(piperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)pyridin-3-yl)acetamide 
• 1393901-67-1 tert-butyl 4-(4-((4-(2-(3-(2-amino-2-oxoethyl)pyridin-2-yl)ethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperidine-1-carboxylate 

Relevant articles and documents

FTO INHIBITORS

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4)

Figure Presented. A survey of PDE4 inhibitors reveals that some compounds trigger intracellular aggregation of PDE4A4 into accretion foci through association with the ubiquitin-binding scaffold protein p62 (SQSTM1). We show that this effect is driven by i